LEUKOCYTE DEPLETION OF RANDOM SINGLE-DONOR PLATELET TRANSFUSIONS DOES NOT PREVENT SECONDARY HUMAN-LEUKOCYTE ANTIGEN-ALLOIMMUNIZATION AND REFRACTORINESS - A RANDOMIZED PROSPECTIVE-STUDY

被引:96
作者
SINTNICOLAAS, K
KOOIJ, MV
VANPROOIJEN, HC
VANDIJK, BA
VANPUTTEN, WLJ
CLAAS, FHJ
NOVOTNY, VMJ
BRAND, A
机构
[1] DR DANIEL DEN HOED CANC CTR, DEPT STAT, BLOOD TRANSFUS SERV, 3008 AE ROTTERDAM, NETHERLANDS
[2] UNIV UTRECHT HOSP, DEPT HEMATOL, UTRECHT, NETHERLANDS
[3] UNIV NIJMEGEN HOSP, BLOOD TRANSFUS SERV, 6500 HB NIJMEGEN, NETHERLANDS
[4] UNIV LEIDEN HOSP, DEPT IMMUNOHAEMATOL, 2300 RC LEIDEN, NETHERLANDS
[5] UNIV LEIDEN HOSP, BLOOD BANK, 2300 RC LEIDEN, NETHERLANDS
[6] RED CROSS, BLOOD BANK LEIDEN, LEIDEN, NETHERLANDS
关键词
D O I
10.1182/blood.V85.3.824.bloodjournal853824
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We studied the value of leukocyte depletion of platelet transfusions for the prevention of secondary human leukocyte antigen (HLA)-alloimmunization in patients with a high-risk of prior immunization induced by pregnancies. Seventy-five female patients with hematologic malignancies (mostly acute leukemia) and a history of pregnancy were randomized to receive either standard random single-donor platelet transfusions (mean leukocytes, 430 x 10(6) per transfusion) or leukocyte-depleted random single-donor platelet transfusions. Leukocyte depletion to less than 5 x 10(6) leukocytes per platelet transfusion (mean leukocytes, 2 x 10(6) per transfusion) was achieved by filtration. Of the 62 evaluable patients, refractoriness to random donor platelets occurred in 41% (14 of 34) of the patients in the standard group and in 29% (8 of 28) of the patients in the filtered group (P = .52); anti-HLA antibodies developed in 43% (9 of 21) of individuals in the standard group and 44% (11 of 25) of cases in the filtered group. The time toward refractoriness and development of anti-HLA antibodies was similar for both groups. We conclude that leukocyte depletion of random single-donor platelet products to less than 5 x 10(6) per transfusion does not reduce the incidence of refractoriness to random donor platelet transfusions because of boostering of anti-HLA antibodies. (C) 1995 by The American Society of Hematology.
引用
收藏
页码:824 / 828
页数:5
相关论文
共 28 条